Meth 2.0 and Opioid Use Disorder: A Collision of Epidemics (Recording)

Friday, July 7, 2023, 12:00 AM - Monday, July 6, 2026, 11:59 PM, On Demand

The goal of the National Institute of Drug Abuse (NIDA) Clinical Trials Network webinar series is to help scholars and clinicians in the addiction field stay abreast of cutting edge science. In 2021, this will include the topics of combined use of opiates and stimulants, the role of stigma in the treatment of addiction and racial disparities in treatment. In this session, Dr. Larissa Mooney discusses recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants will also learn about the treatment approaches to address this rising comorbidity.

  Release Date: July 07, 2023
  Expiration Date: July 06, 2026
  Estimated Time to Complete: 1.5 hours
  Registration Fee: FREE
 *Originally recorded 05/25/2021

View more DEA MATE resources and training accredited by Stanford CME at https://med.stanford.edu/cme/dea.html

AMA PRA Category 1 Credits™ (1.50 hours), Non-Physician Participation Credit (1.50 hours)

1. Recall at least two recent epidemiological trends in co-occurring methamphetamine use and opioid use disorder.
2. Identify at least three medical risks of co-occurring methamphetamine and opioid use.
3. Explain at least three evidence-based treatment approaches that can be utilized with patients who use both methamphetamine and opioids.

In support of improving patient care, this activity has been planned and implemented by Stanford Medicine and Northwest Addiction Technology Transfer Center. Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation

American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Conference Coordinator.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

Bibliography/Works Cited:

Anderson, A. L., Li, S. H., Biswas, K., McSherry, F., Holmes, T., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T., Campbell, J., Haning, W., Mawhinney, J., McCann, M., Rawson, R., Stock, C., Weis, D., Yu, E., & Elkashef, A. M. (2012). Modafinil for the treatment of methamphetamine dependence. Drug and alcohol dependence, 120(1-3), 135–141. https://doi.org/10.1016/j.drugalcdep.2011.07.007

Anderson, A. L., Li, S. H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., Roache, J. D., Stock, C., & Elkashef, A. M. (2015). Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug and alcohol dependence, 150, 170–174. https://doi.org/10.1016/j.drugalcdep.2015.01.036

AshaRani, P. V., Hombali, A., Seow, E., Ong, W. J., Tan, J. H., & Subramaniam, M. (2020). Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug and alcohol dependence, 212, 108060. https://doi.org/10.1016/j.drugalcdep.2020.108060

Buchholz, J., & Saxon, A. J. (2019). Medications to treat cocaine use disorders: current options. Current opinion in psychiatry, 32(4), 275–281. https://doi.org/10.1097/YCO.0000000000000518

Centers for Disease Control and Prevention. NCHS Data Brief 356; Drug Overdose Deaths in the United States, 1999-2018. National Center for Health Statistics, National Vital Statistics System. https://www.cdc.gov/nchs/data/databriefs/db356_tables-508.pdf#4

Centers for Disease Control and Prevention. (2021). Provisional Drug Overdose Death Counts. National Center for Health Statistics, National Vital Statistics System. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Centers for Disease Control and Prevention. (2021). Understanding Drug Overdoses and Deaths. Centers for Disease Control and Prevention. https://www.cdc.gov/drugoverdose/epidemic/index.html

Chan, B., Kondo, K., Ayers, C., Freeman, M., Montgomery, J., Paynter, R., & Kansagara, D. (2018). Pharmacotherapy for Stimulant Use Disorders: A Systematic Review. Department of Veterans Affairs (US).

Coffin, P. O., Santos, G. M., Hern, J., Vittinghoff, E., Walker, J. E., Matheson, T., Santos, D., Colfax, G., & Batki, S. L. (2020). Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA psychiatry, 77(3), 246–255. https://doi.org/10.1001/jamapsychiatry.2019.3655

Colfax, G. N., Santos, G. M., Das, M., Santos, D. M., Matheson, T., Gasper, J., Shoptaw, S., & Vittinghoff, E. (2011). Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Archives of general psychiatry, 68(11), 1168–1175. https://doi.org/10.1001/archgenpsychiatry.2011.124

D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA, 313(16), 1636–1644. https://doi.org/10.1001/jama.2015.3474

Drug Enforcement Administration. (2021). 2020 National Drug Threat Assessment. DEA Methamphetamine profiling program. https://www.dea.gov/sites/default/files/2021-02/DIR-008-21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf

Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008). A meta-analytic review of psychosocial interventions for substance use disorders. The American journal of psychiatry, 165(2), 179–187. https://doi.org/10.1176/appi.ajp.2007.06111851

Economist, The. (2019). Amid the opioid crisis, a different drug comes roaring back. The Economist. https://www.economist.com/united-states/2019/03/09/amid-the-opioid-crisis-a-different-drug-comes-roaring-back

Elkashef, A., Kahn, R., Yu, E., Iturriaga, E., Li, S. H., Anderson, A., Chiang, N., Ait-Daoud, N., Weiss, D., McSherry, F., Serpi, T., Rawson, R., Hrymoc, M., Weis, D., McCann, M., Pham, T., Stock, C., Dickinson, R., Campbell, J., Gorodetzky, C., … Johnson, B. A. (2012). Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction (Abingdon, England), 107(7), 1297–1306. https://doi.org/10.1111/j.1360-0443.2011.03771.x

Elkashef, A., Vocci, F., Hanson, G., White, J., Wickes, W., & Tiihonen, J. (2008). Pharmacotherapy of methamphetamine addiction: an update. Substance abuse, 29(3), 31–49. https://doi.org/10.1080/08897070802218554

Ellis, M. S., Kasper, Z. A., & Cicero, T. J. (2018). Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. Drug and alcohol dependence, 193, 14–20. https://doi.org/10.1016/j.drugalcdep.2018.08.029

Furr-Holden, D., Milam, A. J., Wang, L., & Sadler, R. (2021). African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018. Addiction (Abingdon, England), 116(3), 677–683. https://doi.org/10.1111/add.15233

Galloway, G. P., Buscemi, R., Coyle, J. R., Flower, K., Siegrist, J. D., Fiske, L. A., Baggott, M. J., Li, L., Polcin, D., Chen, C. Y., & Mendelson, J. (2011). A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clinical pharmacology and therapeutics, 89(2), 276–282. https://doi.org/10.1038/clpt.2010.307

Goodnough, A. (2018). This E.R. Treats Opioid Addiction On Demand, That’s Very Rare. The New York Times. https://www.nytimes.com/2018/08/18/health/opioid-addiction-treatment.html

Heinzerling, K. G., Swanson, A. N., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014). Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction (Abingdon, England), 109(11), 1878–1886. https://doi.org/10.1111/add.12636

Heinzerling, K. G., Swanson, A. N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010). Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug and alcohol dependence, 109(1-3), 20–29. https://doi.org/10.1016/j.drugalcdep.2009.11.023 

Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. The American journal of psychiatry, 165(11), 1442–1448. https://doi.org/10.1176/appi.ajp.2008.08020304

Kidorf, M., Neufeld, K., & Brooner, R. K. (2004). Combining stepped-care approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients. Substance use & misuse, 39(13-14), 2215–2238. https://doi.org/10.1081/ja-200034591

Kosten, T., Oliveto, A., Feingold, A., Poling, J., Sevarino, K., McCance-Katz, E., Stine, S., Gonzalez, G., & Gonsai, K. (2003). Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug and alcohol dependence, 70(3), 315–325. https://doi.org/10.1016/s0376-8716(03)00032-2

Lappan, S. N., Brown, A. W., & Hendricks, P. S. (2020). Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis. Addiction (Abingdon, England), 115(2), 201–217. https://doi.org/10.1111/add.14793

Lee, J. D., Nunes, E. V., Jr, Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, J., Peavy, K. M., Ross, S., Salazar, D., Schkolnik, P., Shmueli-Blumberg, D., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet (London, England), 391(10118), 309–318. https://doi.org/10.1016/S0140-6736(17)32812-X

Ling, W., Chang, L., Hillhouse, M., Ang, A., Striebel, J., Jenkins, J., Hernandez, J., Olaer, M., Mooney, L., Reed, S., Fukaya, E., Kogachi, S., Alicata, D., Holmes, N., & Esagoff, A. (2014). Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction (Abingdon, England), 109(9), 1489–1500. https://doi.org/10.1111/add.12608

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane database of systematic reviews, (2), CD002207. https://doi.org/10.1002/14651858.CD002207.pub4

Maxwell J. C. (2014). A new survey of methamphetamine users in treatment: who they are, why they like "meth," and why they need additional services. Substance use & misuse, 49(6), 639–644. https://doi.org/10.3109/10826084.2013.841244

McMahan, V. M., Kingston, S., Newman, A., Stekler, J. D., Glick, S. N., & Banta-Green, C. J. (2020). Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. Drug and alcohol dependence, 216, 108243. https://doi.org/10.1016/j.drugalcdep.2020.108243

Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., Sparenborg, S., & Ling, W. (2016). Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. Journal of addiction medicine, 10(4), 236–243. https://doi.org/10.1097/ADM.0000000000000218

National Institute on Drug Abuse. (2021). Drug Overdose Death Rates. National Institutes of Health. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates

Peirce, J. M., Petry, N. M., Stitzer, M. L., Blaine, J., Kellogg, S., Satterfield, F., Schwartz, M., Krasnansky, J., Pencer, E., Silva-Vazquez, L., Kirby, K. C., Royer-Malvestuto, C., Roll, J. M., Cohen, A., Copersino, M. L., Kolodner, K., & Li, R. (2006). Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Archives of general psychiatry, 63(2), 201–208. https://doi.org/10.1001/archpsyc.63.2.201

Rawson, R. A., Chudzynski, J., Mooney, L., Gonzales, R., Ang, A., Dickerson, D., Penate, J., Salem, B. A., Dolezal, B., & Cooper, C. B. (2015). Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. Drug and alcohol dependence, 156, 21–28. https://doi.org/10.1016/j.drugalcdep.2015.08.029

Rawson, R. A., Huber, A., McCann, M., Shoptaw, S., Farabee, D., Reiber, C., & Ling, W. (2002). A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of general psychiatry, 59(9), 817–824. https://doi.org/10.1001/archpsyc.59.9.817

Severtson, S. G., Kreider, S. E. D., Olsen, H., Ellis, M. S., Cicero, T. J., & Dart, R. C. (2019). The Prevalence of Methamphetamine Use is Increasing Among Individuals Entering Medication-Assisted Treatment Programs for Opioid Use Disorders. RADARS System Technical Report, 2019-Q3. https://www.radars.org/system/publications/2019%203Q%20QTR.pdf

Shoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A. N., De La Garza, R., Newton, T., & Ling, W. (2008). Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and alcohol dependence, 96(3), 222–232. https://doi.org/10.1016/j.drugalcdep.2008.03.010

Srivastava, A., Kahan, M., Njoroge, I., & Sommer, L. Z. (2019). Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Canadian family physician Medecin de famille canadien, 65(5), e214–e220.

Tardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020). Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology, 237(8), 2233–2255. https://doi.org/10.1007/s00213-020-05563-3

Tiihonen, J., Kuoppasalmi, K., Föhr, J., Tuomola, P., Kuikanmäki, O., Vorma, H., Sokero, P., Haukka, J., & Meririnne, E. (2007). A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. The American journal of psychiatry, 164(1), 160–162. https://doi.org/10.1176/ajp.2007.164.1.160

Trivedi, M. H., Greer, T. L., Rethorst, C. D., Carmody, T., Grannemann, B. D., Walker, R., Warden, D., Shores-Wilson, K., Stoutenberg, M., Oden, N., Silverstein, M., Hodgkins, C., Love, L., Seamans, C., Stotts, A., Causey, T., Szucs-Reed, R. P., Rinaldi, P., Myrick, H., Straus, M., … Nunes, E. V. (2017). Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 Stimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. The Journal of clinical psychiatry, 78(8), 1075–1082. https://doi.org/10.4088/JCP.15m10591

Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G., Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S. (2021). Bupropion and Naltrexone in Methamphetamine Use Disorder. The New England journal of medicine, 384(2), 140–153. https://doi.org/10.1056/NEJMoa2020214

Trujillo, K. A., Smith, M. L., & Guaderrama, M. M. (2011). Powerful behavioral interactions between methamphetamine and morphine. Pharmacology, biochemistry, and behavior, 99(3), 451–458. https://doi.org/10.1016/j.pbb.2011.04.014

Tsui, J. I., Mayfield, J., Speaker, E. C., Yakup, S., Ries, R., Funai, H., Leroux, B. G., & Merrill, J. O. (2020). Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. Journal of substance abuse treatment, 109, 80–85. https://doi.org/10.1016/j.jsat.2019.10.005

Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA network open, 3(2), e1920622. https://doi.org/10.1001/jamanetworkopen.2019.20622

Wu, L. T., Zhu, H., & Swartz, M. S. (2016). Treatment utilization among persons with opioid use disorder in the United States. Drug and alcohol dependence, 169, 117–127. https://doi.org/10.1016/j.drugalcdep.2016.10.015

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

At the time the content was created, there were no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity.